Sugi Predict

Sugi Predict / Targets / SUV39H2

SUV39H2

Histone-lysine N-methyltransferase SUV39H2 · Q9H5I1 · SUV39H2 on Sugi Atlas →

21,792 patent compounds predicted against SUV39H2, 6,258 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2738160 SCHEMBL2738160 0.41 16/20
SCHEMBL517615 SCHEMBL517615 0.53 15/20
SCHEMBL291240 SCHEMBL291240 0.40 14/20
SCHEMBL3340439 SCHEMBL3340439 0.35 13/20
SCHEMBL2801999 SCHEMBL2801999 0.52 12/20
SCHEMBL2142043 SCHEMBL2142043 0.50 12/20
SCHEMBL1588740 SCHEMBL1588740 0.54 11/20
SCHEMBL2271966 SCHEMBL2271966 0.52 11/20
SCHEMBL1588447 SCHEMBL1588447 0.50 11/20
SCHEMBL1588448 SCHEMBL1588448 0.50 11/20
SCHEMBL113151 SCHEMBL113151 0.46 11/20
SCHEMBL517675 SCHEMBL517675 0.45 11/20
SCHEMBL2738162 SCHEMBL2738162 0.41 11/20
SCHEMBL3339342 SCHEMBL3339342 0.35 11/20
SCHEMBL1800785 SCHEMBL1800785 0.54 10/20
SCHEMBL517443 SCHEMBL517443 0.50 10/20
SCHEMBL113150 SCHEMBL113150 0.47 10/20
SCHEMBL3281853 SCHEMBL3281853 0.46 10/20
SCHEMBL1691818 SCHEMBL1691818 0.45 10/20
SCHEMBL2738158 SCHEMBL2738158 0.39 10/20

Clinical trials — most relevant to SUV39H2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer PHASE1/PHASE2RECRUITING
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS PHASE1/PHASE2WITHDRAWN
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Tazemetostat and Palbociclib With CPX-351for R/R AML PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Mechanisms of Immune Deficiency nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SUV39H2 binder may also engage these)

ProteinNameSimilarity
Q4R3E0 — 1.000 Q4R3E0 →
Q32PH7 — 1.000 Q32PH7 →
Q28CQ7 — 1.000 Q28CQ7 →
Q5F3W5 — 0.998 Q5F3W5 →
Q6DGD3 — 0.998 Q6DGD3 →
Q6NRE8 — 0.994 Q6NRE8 →
Q9EQQ0 — 0.993 Q9EQQ0 →
O54864 — 0.993 O54864 →
SUV39H1 Histone-lysine N-methyltransferase SUV39H1 0.992 landscape →
Q2NL30 — 0.991 Q2NL30 →
Q5RB81 — 0.991 Q5RB81 →
Q80UJ9 — 0.990 Q80UJ9 →
Q945S8 — 0.988 Q945S8 →
Q8GZB6 — 0.987 Q8GZB6 →
Q5I0M0 — 0.985 Q5I0M0 →
Q949T8 — 0.985 Q949T8 →
Q9M1X9 — 0.985 Q9M1X9 →
Q8W595 — 0.984 Q8W595 →
P45975 — 0.981 P45975 →
Q294B9 — 0.981 Q294B9 →
Q0VD24 — 0.980 Q0VD24 →
Q09265 — 0.980 Q09265 →
Q5ZJM3 — 0.980 Q5ZJM3 →
Q5E9T7 — 0.980 Q5E9T7 →
Q95K79 — 0.980 Q95K79 →
Q8R5C8 — 0.980 Q8R5C8 →
Q6YI93 — 0.980 Q6YI93 →
Q9C5P1 — 0.980 Q9C5P1 →
Q96BT7 — 0.979 Q96BT7 →
O60016 — 0.979 O60016 →